| |
Total patients (%)
|
CF Patients (%)
|
HS Patients (%)
|
P Value
|
|---|
|
No.
|
339
|
141 (41.59)
|
198 (58.41)
| |
|
Mean age (range)
|
60 (22–86)
|
52 (22–79)
|
62.5 (38–86)
|
<0.001
|
|
Histology
| | | |
NS
|
|
ILC
|
30 (8.8)
|
12 (8.5)
|
18 (9.1)
| |
|
IDC
|
299 (88.2)
|
126 (89.4)
|
173 (87.4)
| |
|
Intraductal
|
10 (3)
|
3 (21)
|
7 (3.5)
| |
|
T stage
| | | |
NS
|
|
T1
|
293 (86.4)
|
121 (85.8)
|
172 (86.7)
| |
|
T2
|
46 (13.6)
|
20 (14.2)
|
26 (13.3)
| |
|
N stage
| | | |
NS
|
|
Nx
|
21 (6,3)
|
8 (5,7)
|
13 (6,5)
| |
|
N0
|
251 (74)
|
93 (65.9)
|
158 (79.8)
| |
|
N1
|
67 (19.7)
|
32 (22.6)
|
35 (17.6)
| |
|
Grading (Bloom Richardson’s scale)
| | | |
NS
|
|
G1
|
60 (17.7)
|
22 (15.6)
|
38 (19.2)
| |
|
G2
|
131 (38.6)
|
58 (41.1)
|
73 (36.8)
| |
|
G3
|
79 (23.3)
|
36 (25.5)
|
43 (21.7)
| |
|
NA
|
69 (20.4)
|
25 (17.8)
|
44 (22.3)
| |
|
Surgical margins
| | | |
NS
|
|
Negative
|
295 (87)
|
124 (87.9)
|
171 (86.4)
| |
|
Positive
|
5 (1.5)
|
2 (1.4)
|
3 (1.5)
| |
|
Close (< 2 mm)
|
27 (8)
|
10 (7.1)
|
17 (8.6)
| |
|
Tangents
|
12 (3.5)
|
5 (3.6)
|
7 (3.5)
| |
|
Breast Volume
| | | | |
|
Average cc
|
718.7
|
684
|
725.4
|
NS
|
|
(range)
|
(188.6-2036.7)
|
(188.6-1899.9)
|
(193.3-2036.7)
|
|
Chemotherapy
| | | | |
|
Yes
|
126 (37.2)
|
68 (48.2%)
|
58 (29.3%)
| |
|
No
|
211 (62.2%)
|
72 (51.1%)
|
139 (70.2%)
|
0.008
|
|
NA
|
2 (0.6%)
|
1 (0.7%)
|
1 (0.5%)
| |
|
Hormone therapy
| | | | |
|
Yes
|
247 (72.8)
|
101 (71.6)
|
146 (73.7)
|
NS
|
|
No
|
74 (21.8)
|
34 (24.1)
|
40 (20,2)
| |
|
NA
|
18 (5.4)
|
6 (4.3)
|
12 (6.1)
| |
|
Trastuzumab
| | | | |
|
Yes
|
17 (5)
|
7 (5)
|
10 (5)
|
NS
|
|
No
|
327 (95)
|
134 (95)
|
188 (95)
| |
- CF: Conventional Fractionation; HS: Hypofractionated Schedule; ILC: infiltrating lobular carcinoma; IDC: infiltrating ductal carcinoma; NA: not available; NS: not significant (P>0.05).
